Allphase Pharma Consulting, LLC
A Professional Service Provider for the Pharma Industry
Two posters on tacicepts caught our eyes. First is the Tumlin publication on povetacicept, an oral presentation in the “Late-Breaking Research” session. This is an interim look at Phase 1b study data reporting on 17 IgAN patients treated for 48 weeks with a dose of 80 mg and 30 patients Continue reading TACICEPTS VYING FOR YOUR ATTENTION
Shortly after posting our last blog on tacicepts, new data was published in the NEJM on the pivotal Phase 3 trial of atacicept. This publication by Lafayette et al. provides results from an IA of the ongoing ORIGIN-3 trial.[1] We updated our table with this new information that centers on Continue reading COMPARISON OF BAFF / APRIL INHIBITORS – 2
First, a reminder where the name ‘Berger’s disease’ or Morbus Berger comes from. It was Jean Berger, a French pathologist and doctor, who initially identified IgA deposits on the glomeruli of nephritic patients. This was not so long ago; his publication (in French) dates from 1968.[1] Now the race is heating Continue reading COMPARISON OF BAFF / APRIL INHIBITORS